Ownership Capital B.V. Cuts Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Ownership Capital B.V. decreased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 6.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 791,187 shares of the life sciences company’s stock after selling 58,462 shares during the quarter. Illumina accounts for about 3.9% of Ownership Capital B.V.’s holdings, making the stock its 14th biggest holding. Ownership Capital B.V. owned about 0.50% of Illumina worth $105,726,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Versant Capital Management Inc increased its stake in shares of Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after buying an additional 146 shares during the period. Golden State Wealth Management LLC purchased a new stake in shares of Illumina in the 4th quarter valued at approximately $32,000. TD Private Client Wealth LLC raised its holdings in shares of Illumina by 58.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after purchasing an additional 141 shares in the last quarter. V Square Quantitative Management LLC lifted its position in shares of Illumina by 50.6% during the 4th quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company’s stock worth $52,000 after purchasing an additional 132 shares during the last quarter. Finally, Private Trust Co. NA grew its stake in shares of Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after purchasing an additional 212 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on ILMN. TD Cowen downgraded Illumina from a “buy” rating to a “hold” rating and dropped their price objective for the company from $177.00 to $140.00 in a report on Friday, February 7th. Canaccord Genuity Group dropped their price target on shares of Illumina from $145.00 to $135.00 and set a “hold” rating on the stock in a research note on Friday, February 7th. Citigroup downgraded shares of Illumina from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $190.00 to $165.00 in a research report on Wednesday, December 11th. Guggenheim lowered their target price on shares of Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a report on Friday, February 7th. Finally, Royal Bank of Canada cut their price target on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $159.45.

Illumina Price Performance

ILMN stock opened at $102.98 on Thursday. The firm has a 50 day moving average of $129.96 and a 200-day moving average of $134.41. The company has a market cap of $16.31 billion, a price-to-earnings ratio of -13.41, a PEG ratio of 1.66 and a beta of 1.10. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 12-month low of $99.33 and a 12-month high of $156.66.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, equities analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.